Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
Aytu BioPharma (Nasdaq: AYTU) announced that CEO Josh Disbrow will participate in a fireside chat at the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026 at 5:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aytu BioPharma (Nasdaq: AYTU) announced that CEO Josh Disbrow will participate in a fireside chat at the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026 at 5:00 p.m. ET. The session is moderated by Thomas Flaten, senior research analyst at Lake Street Capital Markets.
The event will be available via webcast at https://lythampartners.com/hc2026/aytu and on the conference home page, with a replay accessible through the same links.
Details
News Market Reaction – AYTU
On Jan 14, the first trading day after this news, AYTU closed 4.56% above the previous close.
Data tracked by StockTitan Argus for the Jan 14 session.
Key Figures
- Webcast time
- 5:00 p.m. Eastern time
- Lytham Partners 2026 Investor Healthcare Summit fireside chat
- Event date
- January 15, 2026
- Scheduled date of the investor healthcare summit webcast
Historical Context
-
Announced January 2026 Investor Day focused on EXXUA and KOL discussions.
-
Announced U.S. commercial availability of EXXUA for major depressive disorder.
-
Disclosed management presentation at NobleCon21 and webcast availability.
-
Reported Q1 fiscal 2026 revenue, net income, cash, and EXXUA patent extension.
-
Announced timing and access details for upcoming Q1 fiscal 2026 results call.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, CO / ACCESS Newswire / January 13, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, announced today that Josh Disbrow, Chief Executive Officer of Aytu, will participate in a fireside chat moderated by Thomas Flaten, Senior Research Analyst at Lake Street Capital Markets, at the Lytham Partners 2026 Investor Healthcare Summit.
The webcast will take place at 5:00 p.m. Eastern time on Thursday, January 15, 2026. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/hc2026/ or directly at https://lythampartners.com/hc2026/aytu. A replay will also be available through the same links.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com
Robert Blum
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.